The Peptide Paradox in Pharmacology of Obesity

Authors

  • Sanjay Kalra Department of Endocrinology, Bharti Hospital, Karnal, India; University Center for Research & Development, Chandigarh University, Mohali, India;
  • Amandeep Singh Department of Medicine, All India Institute of Medical Sciences, New Delhi, India;
  • Nitin Kapoor Department of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore, India; Non communicable disease unit, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.

DOI:

https://doi.org/10.47391/JPMA.25-53

Abstract

Peptide biology is a fascinating subject, and peptide
pharmacology even more so. Peptides have multiple bodily
functions, including their work as hormones and metabolic
modulators. However, certain pharmacodynamic and
kinetic properties of peptides used in obesity result in
paradoxical outcomes. It is helpful for the treating clinician
to be aware of these peptide paradoxes, which not only
help in understanding the rationale of using these drugs
but also help to explain their differences in clinical actions.

Keywords: biological paradox, dual agonists, GIP receptor
agonists, GLP receptor agonists, glucagon agonists,
peptide biology, semaglutide, tirzepatide, triple agonists,

Published

2025-07-01

How to Cite

Sanjay Kalra, Amandeep Singh, & Nitin Kapoor. (2025). The Peptide Paradox in Pharmacology of Obesity. Journal of the Pakistan Medical Association, 75(07), 1138–1140. https://doi.org/10.47391/JPMA.25-53

Issue

Section

RECENT ADVANCES IN ENDOCRINOLOGY

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>